Clinical trial · Observational
Patients Undergoing Pancreatic Surgery at the Antwerp University Hospital.
Pancreatic Surgery Registry (PANREG)
NCT07443761CI-TRIAL-00104397PANREGactive not recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
There is a need for a structured registry to collect real-world data on patient characteristics, surgical strategies, perioperative outcomes, and long-term results. Such a registry will provide insights into quality of care, support benchmarking, and form the basis for clinical and translational research.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Benign Pancreas Tumor | Benign Pancreatic Neoplasm | ALIAS | 0.90 |
| Malignant Pancreatic Neoplasm | Malignant Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- 90-day mortality
- timeFrame
- 25 years
- description
- 90-day mortality
Secondary outcomes (1)
- measure
- Establishment of a registry for patients undergoing pancreatic surgery - secondary outcome measures
- timeFrame
- 25 years
- description
- * 30-day mortality * morbidity, expressed as specific postpancreatectomy complications ( = defined by the ISPGS (International Study Group for Pancreatic Surgery), i.e. POPF (postoperative pancreatic fistula), chyle leak, PPH (postpancreatectomy haemorrhage), bile leak and delayed gastric emptying), postoperative complications defined by the Clavien Dindo scoring and the CCI (comprehensive complication index) * duration of hospital stay * need for postoperative transfusion * development of exocrine- or endocrine insufficiency (through systematic postoperative function testing) * overall survival * disease free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * benign indications for pancreatic surgery, including chronic pancreatitis, cystic lesions and IPMN * malignant indications for pancreatic surgery, including PDAC, duodenal carcinoma, pancreatic neuro-endocrine tumours, distal cholangiocarcinoma. Exclusion criteria: * indications for pancreatic resection caused by acute pancreatitis * pancreatic resection after abdominal trauma
References
Publications (3)
- BACKGROUNDHartman V, Bracke B, Chapelle T, Hendrikx B, Liekens E, Roeyen G. Robotic Pancreaticoduodenectomy for Pancreatic Head Tumour: A Single-Centre Analysis. Cancers (Basel). 2024 Dec 20;16(24):4243. doi: 10.3390/cancers16244243. PMID 39766142
- BACKGROUNDHo CK, Kleeff J, Friess H, Buchler MW. Complications of pancreatic surgery. HPB (Oxford). 2005;7(2):99-108. doi: 10.1080/13651820510028936. PMID 18333171
- BACKGROUNDPancreasGroup.org Collaborative. Pancreatic surgery outcomes: multicentre prospective snapshot study in 67 countries. Br J Surg. 2024 Jan 3;111(1):znad330. doi: 10.1093/bjs/znad330. PMID 38743040